Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756148 | 0.84 | OPRM1 (0.72) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL9917103 | 0.82 | OPRM1 (0.97) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL14894612 | 0.81 | OPRM1 (0.67) | OPRM1SLC6A4 | |
| SCHEMBL13284143 | 0.80 | OPRM1 (0.97) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| Hydrochloric Acid SCHEMBL6167759 | 0.80 | OPRM1 (0.68) | OPRM1SLC6A4 | |
| Meperidine SCHEMBL25431 | 0.80 | OPRM1 (1.00) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| Hydroxypethidine SCHEMBL25246 | 0.80 | OPRM1 (0.74) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| Hydroxypethidine SCHEMBL29966554 | 0.80 | OPRM1 (0.74) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL4657230 | 0.79 | OPRM1 (0.64) | OPRM1SLC6A4 | |
| SCHEMBL14894296 | 0.79 | OPRM1 (0.64) | OPRM1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245572-A1 | Naphthyl ether compounds and their use | OLINK AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1546101-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004022539-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245572-A1 | Naphthyl ether compounds and their use | NR4A1, NPM1, H1-4 | OPRM1 743/4885SLC22A1 4424/4885SLC6A4 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.